Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction

Abstract

In patients admitted for acute myocardial infarction, the communication and transition from specialists to primary care physicians is often delayed, and the information imparted to subsequent healthcare providers (HCPs) may be sub-optimal. A French group of cardiologists, lipidologists and diabetologists decided to establish a consensus to optimize the discharge letter after hospitalization for acute myocardial infarction. The aim is to improve both the timeframe and the quality of the content transmitted to subsequent HCPs, including information regarding baseline assessment, procedures during hospitalization, residual risk, discharge treatments, therapeutic targets and follow-up recommendations in compliance with European Society of Cardiology guidelines. A consensus was obtained regarding a template discharge letter, to be released within two days after patient’s discharge, and containing the description of the patient’s history, risk factors, acute management, risk assessment, discharge treatments and follow-up pathway. Specifically for post acute MI patients, tailored details are necessary regarding the antithrombotic regimen, lipid-lowering and anti-diabetic treatments, including therapeutic targets. Lastly, the follow-up pathway needs to be precisely mentioned in the discharge letter. Additional information such as technical descriptions, imaging, and quality indicators may be provided separately. A template for a standardized discharge letter based on 8 major headings could be useful for implementation in routine practice and help to improve the quality and timing of information transmission between HCPs after acute MI.

Keywords

Myocardial infarction discharge;primary care communication

Get full access to this article

View all access options for this article.

References

Van Walraven

Rokosh

. What is necessary for high-quality discharge summaries? Am J Med Qual 1999; 14: 160–169.

Kripalani

LeFevre

Phillips

et al. Deficits in communication and information transfer between hospital-based and primary care physicians: Implications for patient safety and continuity of care. JAMA 2007; 297: 831–841.

Goldman

Pantilat

Whitcomb

WF.

Passing the clinical baton: 6 principles to guide the hospitalist. Am J Med 2001; 111: 36S–39S.

Piepoli

Corra

Dendale

et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol 2016; 23: 1994–2006.

Jernberg

Hasvold

Henriksson

et al. Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36: 1163–1170.

Bado

Williams

CJ.

Usefulness of letters from hospitals to general practitioners. Br Med J (Clin Res Ed) 1984; 288: 1813–1814.

Ibanez

James

Agewall

et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.

Roffi

Patrono

Collet

et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.

Jones

Hunter

Consensus methods for medical and health services research. BMJ 1995; 311: 376–380.

10.

Valgimigli

Bueno

Byrne

et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213–260.

11.

Yusuf

Zhao

Mehta

et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

12.

Wallentin

Becker

Budaj

et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

13.

Wiviott

Braunwald

McCabe

et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

14.

Morrow

Braunwald

Bonaca

et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404–1413.

15.

Mega

Braunwald

Wiviott

et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.

16.

Bonaca

Braunwald

Sabatine

MS.

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 373: 1274–1275.

17.

Mauri

Yeh

Kereiakes

DJ.

Duration of dual antiplatelet therapy after drugeluting stents. N Engl J Med 2015; 372: 1373–1374.

18.

Eikelboom

Connolly

Bosch

et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319–1330.

19.

Costa

van Klaveren

James

et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025–1034.

20.

Yeh

Secemsky

Kereiakes

et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315: 1735–1749.

21.

Catapano

Graham

De Backer

et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

22.

Piepoli

Hoes

Agewall

et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381.

23.

Ferrieres

Lautsch

Ambegaonkar

et al. Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. Int J Cardiol 2018; 270: 21–27.

24.

Fox

Tai

Kostev

et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 2018; 107: 380–388.

25.

Gitt

Lautsch

Ferrieres

et al. Cholesterol target value attainment and lipidlowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158–166.

26.

Reiner

de Backer

Fras

et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries—Findings from the EUROASPIRE IV survey. Atherosclerosis 2016; 246: 243–250.

27.

Bruckert

Hayem

Dejager

et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–414.

28.

Nielsen

Nordestgaard

BG.

Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study. Eur Heart J 2016; 37: 908–916.

29.

Leeper

Ardehali

deGoma

et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 2007; 116: 613–618.

30.

Cannon

Blazing

Giugliano

et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

31.

Giugliano

Pedersen

Park

et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390: 1962–1971.

32.

Schiele

Farnier

Krempf

et al. A consensus statement on lipid management after acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2018; 7: 532–543.

33.

Green

Bethel

Armstrong

et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.

34.

Marso

Bain

Consoli

et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.

35.

Marso

Daniels

Brown-Frandsen

et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.

36.

Neal

Perkovic

Mahaffey

et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

37.

Zinman

Wanner

Lachin

et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

38.

Pieber

Marso

McGuire

et al. DEVOTE 3: Temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018; 61: 58–65.

39.

Inzucchi

Bergenstal

Buse

et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429–442.

40.

Lloyd

Barnett

Use of problem lists in letters between hospital doctors and general practitioners. BMJ 1993; 306: 247.

41.

Rawal

Barnett

Lloyd

BW.

Use of structured letters to improve communication between hospital doctors and general practitioners. BMJ 1993; 307: 1044.

42.

Braun

Hagen

Smith

et al. Oncologists and family physicians. Using a standardized letter to improve communication. Can Fam Physician 2003; 49: 882–886.

43.

Taylor

Cameron

PA.

Discharge instructions for emergency department patients: What should we provide?

J Accid Emerg Med 2000; 17: 86–90.

44.

Guidelines and Audit Implementation Network. Guidelines on regional immediate discharge documentation for patients being discharged from secondary into primary care. https://www.rqia.org.uk/RQIA/files/73/734a792f-f9d4-47f0-830f-31f9db51c82a.pdf (2022, accessed 8 April 2019).

45.

Canadian Institute for Health Information. Improving timeliness of discharge abstract database data, https://secure.cihi.ca/free_products/ImprovingTimeliness.pdf (2000, accessed 8 April 2019).

46.

National Quality Forum: Safe practices for better healthcare, http://www.qualityforum.org/Publications/2010/04/Safe_Practices_for_Better_Healthcare_%E2%80%93_2010_Update.aspx (2003, accessed 8 April 2019).

47.

Haute Autorite de Sante. Document de sortie d’hospitalisation Vers un format électronique, https://www.has-sante.fr/portail/jcms/c_1777678/fr/document-de-sortie-dhospitalisation-superieure-a-24h (2014, accessed 8 April 2019).

48.

Haute Autorite de Sante. Fiche descriptive de l’indicateur de qualité et de sécurité des soins « Qualité de la lettre de liaison à la sortie ». https://www.has-sante.fr/portail/upload/docs/application/pdf/2015-12/fiche_descriptive_qds_mco_9.12.2015.pdf (2018, accessed 8 April 2019).

49.

The Scottish Intercollegiate Guidelines Network (SIGN), https://www.sign.ac.uk/sign-128-the-sign-discharge-document.html (2012, accessed 8 April 2019).

50.

Health Information and Quality Authority. National standard for patient discharge summary information, https://www.hiqa.ie/sites/default/files/2017-01/National-Standard-Patient-Discharge-Summary.pdf (2013, accessed 8 April 2019).

51.

Professional Records Standards Body. https://theprsb.org/standards/edischargesummary/ (2019, accessed 8 April 2019).

52.

Motamedi

Posadas-Calleja

Straus

et al. The efficacy of computer-enabled discharge communication interventions: A systematic review. BMJ Qual Saf 2011; 20: 403415.

53.

Doyle

Malcolm

Liu

et al. Using a structured discharge letter template to improve communication during the transition from a specialized outpatient diabetes clinic to a primary care physician. Can J Diabetes 2015; 39: 457–466.

54.

Cherlin

Curry

Thompson

et al. Features of high quality discharge planning for patients following acute myocardial infarction. J Gen Intern Med 2013; 28: 436443.

55.

Mercado

Smith

McConnon

ML.

Myocardial infarction: Management of the subacute period. Am Fam Physician 2013; 88: 581–588.

56.

Lemesle

Lamblin

Meurice

et al. Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates, and impact on prognosis (from the Suivi d’une cohorte de patients COROnariens stables en region NORdPas-de-Calais study). Am Heart J 2014; 168: 479–486.

57.

Kunz

Wegscheider

Guyatt

et al. Impact of short evidence summaries in discharge letters on adherence of practitioners to discharge medication. A cluster-randomised controlled trial. Qual Saf Health Care 2007; 16: 456–461.